Our results are similar to two recent in vivo studies that found hepatic FGF21 expression was activated, and serum FGF21 levels were increased in response to hepatocarcinogenesis, breast cancer, primary renal tumors, and papillary thyroid cancer12,33–35. Here, FGF21 is linked to breast cancer.